Today's News

Vancouver, BC, August 7, 2018--(T-Net)--Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that the first patient in the RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn's disease has been enrolled.

The first stage of this trial is actively recruiting participants at sites in Vancouver BC, New Westminster BC and Hamilton ON.

Building on the results from Qu's initial clinical trial in Crohn's disease, the aim of this study is to further establish the safety and efficacy of the investigational drug QBECO SSI for the induction of clinical and endoscopic response and remission. QBECO SSI is intended to restore innate immune function and achieve sustained remission off all medications.

"Qu's QBECO SSI is designed to correct the innate immune suppression that underlies Crohn's disease, unlike current drugs that treat the end result of the disease by suppressing immune function," stated Dr. Hal Gunn, MD, CEO Qu Biologics. "By restoring innate immune function, we are hopeful that our novel treatment approach may achieve long-term remission or cure off medications."

Qu Biologics is recruiting a total of 20 adult Canadian residents with active moderate-to-severe Crohn's disease for the open-label stage of the RESTORE trial. Every participant will receive QBECO SSI treatment for up to 52 weeks. The results from this stage of the study will inform a subsequent 150 patient randomized controlled trial which will recruit internationally.

For information about this Crohn's disease clinical trial, visit www.restoretrial.ca and www.quibd.com.

For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com.

About Qu Biologics

Qu Biologics is a clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies designed to stimulate an innate immune response in targeted organs to reverse the chronic inflammation underlying many important diseases including inflammatory bowel disease, cancer, inflammatory lung disease and arthritis. Qu has completed three Phase 2 studies in Crohn's disease, ulcerative colitis and lung cancer.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally.